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INTRODUCTION
Multiple endocrine neoplasia type 1 (MEN1) is
characterized by the combined occurrence of tu-
mors of parathyroid glands, pancreatic endocrine
and anterior pituitary. The “multiple” designation
refers both to the occurrence of tumors in multiple
endocrine organs (e.g., parathyroid tumors plus
pancreatic endocrine tumors) and to the occur-
rence of multiple tumors in the involved endocrine
organ (e.g., multiple pancreatic endocrine tumors).
MEN1 is inherited in an autosomal dominant fash-
ion with high penetrance, or may occur sporadi-
cally i.e. without a family history. Defining the fea-
tures of disease manifestation in MEN1 has improved
patient management and treatment. In this review,
the clinical features of MEN1 including those of
Japanese patients and the genetic features of MEN1
will be discussed.
Clinical features of MEN1
The clinical manifestations of MEN1 are related
to the sites of tumors and mainly to their secreted
hormones. In addition to the triad of parathyroid,
pancreatic and pituitary tumors, which constitute the
major components of MEN1, adrenocortical, carcinoid,
and lipomatous tumors have also been described
(1-4). Accurate data on the population prevalence
of MEN1 do not exist. The prevalence of MEN1
has been estimated as 2-10 per 100,000 based on bio-
chemical data (1). The most precise data may be de-
rived from patients having at least one endocrinopathy.
Evidence of MEN1 is detected in the following unselected
patients : 2% to 18% with primary hyperparathyroidism,
15% to 40% with Zollinger-Ellison syndrome, 4% with
insulinoma, and 2% to 5% with pituitary adenomas
(1, 3).
The clinical course of MEN1 over a patient’s life
time can be quite variable. Clinically, overt MEN1
is usually recognized during the fourth or fifth dec-
ade of life. Intra-as well as interfamily comparison
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of the clinical course of the syndrome shows great
variability in the age and pattern of disease expres-
sion. MEN1 tumors except for pituitary tumors be-
gin approximately one or two decades earlier than
sporadic tumors. Tumor multiplicity in one endo-
crine organ in MEN1 is most evident in the para-
thyroid glands and endocrine pancreas. In contrast,
reports describing multiple pituitary adenomas in
MEN1 are rare (5-7). The mutant MEN1 gene has
a high age-related penetrance (i.e. the proportion
of gene carriers manifesting symptoms or signs of
the disease by a given age), being>50% penetrant
by 20 years of age and >95% penetrant by 40 years
(8).
Primary hyperparathyroidism is the most com-
mon manifestation of MEN1 and occurs in more than
95% of all MEN1 patients (1-4). Hyperparathyroidism
is typically the first manifestation of MEN1. Multiple
parathyroid glands are enlarged in association with
primary hyperparathyroidism in MEN1, and the
enlargement is usually quite asymmetric. Surgical
removal of the abnormally overactive parathyroids
is the definitive treatment.
The incidence of pancreatic endocrine tumors in
MEN1 patients varies from 30 to 80% (1-4). The ma-
jority of these tumors produce excessive amounts
of hormone, for example gastrin, insulin, glucagon
or vasoactive intestinal polypeptide (VIP). Gastrinomas
(with the Zollinger-Ellison syndrome), which gen-
erally originate in the pancreas or duodenum, rep-
resent approximately 50% of all pancreatic endo-
crine tumors in MEN1, and are the major cause of
disease-related death in MEN1 patients. The ideal
treatment for a non-metastatic gastrinoma is surgi-
cal excision. Medical treatment of MEN1 patients
with Zollinger-Ellison syndrome is achieved using
proton-pump inhibitors. Insulinomas represent one-third
of all pancreatic endocrine tumors inMEN1 patients.
Patients with an insulinoma present with hypogly-
cemic symptoms. Endoscopic ultrasound and se-
lective arterial infusion of calcium have been sug-
gested as effective in localizing insulinomas. Surgical
treatment has been more often successful.
The incidence of pituitary tumors in MEN1 pa-
tients varies from 15 to 60% in different series (1-4).
The widely varying prevalence rate for pituitary tu-
mors in MEN1 among reports may be tied to biases
in patient selection and to the methods used to test
patients for the feature. The majority of pituitary
adenomas are prolactinomas, followed by growth
hormone (GH)-secreting tumors, non-functioning
tumors, and adenocorticotrophin-secreting tumors.
The clinical manifestations depend upon the size of
the pituitary tumor and its product of secretion.
Treatment of pituitary tumors in MEN1 patients is,
in principle, the same as for sporadic tumors.
Adrenocortical tumors, carcinoid tumors, and
lipomas have also been observed in association
with MEN1 (1-4). The carcinoid tumor may be lo-
cated in the bronchi, the gastrointestinal tract, the
pancreas, or the thymus. Thymic and bronchial
carcinoid tumors have malignant potential.
Review of MEN1 patients in Japan
To clarify the clinical features of MEN1 in Japan,
we searched case reports of MEN1 (9, 10). In prac-
tice, a working definition of MEN1 is a case with
at least two of the three main endocrine expres-
sions of MEN1. The study included case reports of
autopsy. One hundred and forty-three patients were
reported from 1966 to 1995 : 59 patients from 27
families (familial type) and 84 patients without family
history (sporadic type). The mean age of diagnosis
of MEN1 was 41.3 (range 14-74) years in familial
MEN1 and 45.8 (range 9-86) years in sporadicMEN1.
At diagnosis of MEN1, parathyroid tumors were
present in 89%, pancreatic endocrine tumors in 67%,
pituitary tumors in 62%, adrenocortical tumors in
20%, thyroid tumors in 22%, carcinoid tumors in 8%,
and lipoma in 3% of patients. The pattern of gland
involvement inMEN1 is shown in Table 1. In pituitary
tumors,46% of patients showed visual field disturbance,
exhibited hypopituitarism, or were nonsymptomatic.
The remainder showed acromegaly or gigantism,
amenorrhoea-galactorrhea syndrome, or Cushing
disease (Table 2). As described above, prolactinomas
were most common in Caucasians (1-4). Larger
numbers of sporadic MEN1 cases or autopsy cases
in our Japanese cases than in Caucasian populations
may be related to the different prevalence rate for
subtypes of pituitary tumors. In pancreatic endo-
crine tumors, Zollinger-Ellison syndrome due to
gastrinomas was most common, followed by hypo-
glycemia due to insulinomas (Table 3). VIP, para-
thyroid hormone-related protein (PTHrP), and growth
hormone-releasing hormone (GHRH)-secreting pancreatic
tumors were seen less frequently (11). Clinical mani-
festations of primary hyperparathyroidism as part
of MEN1 are shown in Table 4. Our results suggest
that the prevalence of MEN1 is lower in Japan. How-
ever, MEN1 seems not to be rare in Japan, because
Japanese MEN1 case reports have progressively
increased since the recent discovery of the MEN1
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gene.
Mapping and identification of the MEN1 gene
The gene for MEN1 was assigned to chromo-
some 11q13 by linkage analysis in 1988 (12). By
comparing constitutional and tumor tissue genotypes
of pancreatic endocrine tumors as well as parathyroid
tumors, loss of heterozygosity (LOH) involving
polymorphic loci from chromosome 11 in tumors
was frequently disclosed (13-16) (Figure 1). Re-
garding pituitary tumors, we first reported LOH on
chromosome 11 in a GH and prolactin-secreting
adenoma (17). In addition, we first reported common
LOH on chromosome 11 in tumors in three separate
organs in an MEN1 patient (5).
The lost allele was found to be consistently derived
from the unaffected parent, leaving only the mutated
MEN1 allele in the tumors (Figure 2). LOH studies
in MEN1-associated tumors and sporadic endocrine
tumors helped to narrow the location of the MEN1
gene to within an area of 600-kb (18, 19). Focusing
on this smaller region, 12 transcripts were identified
and mapped.
The MEN1 gene was finally identified because it
was the one that contained mutations in most DNAs
from MEN1 patients (20, 21). The gene consists of
10 exons (one untranslated) with a 1,830 bp coding
region (Figure 3). It encodes a 610 amino acid pro-
tein, referred to as menin (20). Expression of the
MEN1 gene has been identified in all normal tissues
tested, and is not restricted to target organs of MEN1.
Germline mutations in MEN1 cases
Except for one large 11q13 deletion (22), rec-
ognized MEN1 mutations have been single-base
substitutions, small insertions, or small deletions.
Pannett and Thakker summarized the reported
germline mutations of theMEN1 gene (4). In 262 pa-
tients, 22% are nonsense mutations, 48% are frameshift
Table 1. Pattern of gland involvement in MEN1 ; evaluation of 143 MEN1 cases reported in the
literature 1966-1995 in Japan
Pattern of involvement Number of patients (%)
Parathyroids, pituitary, and endocrine pancreas
Parathyroids and endocrine pancreas
Parathyroids and pituitary
Pituitary and endocrine pancreas
Parathyroids*
Pituitary*
Endocrine pancreas*
48
37
27
9
16
4
2
34
26
19
6
11
3
1
* cases with family history
Table 2. Clinical syndromes caused by pituitary tumors inMEN1
Clinical manifestation Number of patients (%)
Acromegaly
Gigantism
Amenorrhea-galactorrhea
Cushing disease
Hypopituitarism
Local signs of tumor growth
Asymptomatic tumors
21
1
16
6
1
14
23
26
1
20
7
1
17
28
Table 3. Clinical syndromes and symptoms caused by pancreatic
endocrine tumors in MEN1
Clinical manifestation Number of patients (%)
Zollinger-Ellison syndrome
Hypoglycemia
WDHA syndrome
Ectopic GHRH syndrome
Hypercalcemia by PTHrP
producing tumor
37
30
4
2
1
50
41
5
3
1
Table 4. Clinical manifestation of primary hyperparathyroidism
as a part of MEN1
Clinical presentation Number of patients (%)
Biochemical hyperparathyroidism
Urolithiasis
Bone disease (ostitis fibrosa)
Hyperparathyroid crisis
Acute pancreatitis
59
36
21
3
1
57
35
18
3
1
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Fig.1. Loss of alleles on chromosome 11 in an insulinoma from a patient with MEN1. The restriction fragment length polymor-
phisms (RFLPs) obtained from the patient’s leukocytes (W) and insulinoma (T) DNA using the probes CALCA, D11S325, CAT,
INT 2, ETS1, APOA1, and PBGD are shown. For example, the leukocytes are heterozygous in the CALCA locus (allele 1, 2), but the
tumor cells lost allele 2. Similar losses of alleles are detected by the use of other DNA probes, and an extensive loss of alleles involv-
ing the whole of chromosome 11 is observed. The patient corresponds to case number 7 in Table 2 of reference 23.
Fig. 2. Combined pedigree and tumor analysis. The alleles obtained with probes from HRAS1, D11S149, F2, and D11S527 on chro-
mosome 11 in patient II-1 and her parents (I-1 and I-2). The alleles were obtained by Southern blot analysis, polymerase chain
reaction-RFLP, or microsatellite analysis of leukocytes and pituitary adenomas, parathyroid tumors, and pancreatic endocrine tu-
mors. The mother (I-2) was affected and the father (I-1) was unaffected. The leukocyte genotype of the affected daughter (II-1) was
heterozygous at all 4 loci. An examination of tumor genotypes indicated hemizygosity with the loss of the paternal chromosome 11.
The patients II-1 and I-2 correspond to case numbers 2 and 3, respectively, in Table 2 of reference 23.
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deletions or insertions, 8% are in-frame deletions
or insertions, 5% are donor-splice site mutations and
17% are missense mutations. Germline mutations
in our Japanese MEN1 patients and somatic muta-
tions in a sporadic pituitary adenoma and parathyroid
tumor were identified (Figure 3) (23). Diversity of
MEN1 mutations was observed in Japanese MEN1
patients, as reported in Caucasians (4). Approxi-
mately 10% of the MEN1 mutations arise de novo
and may be transmitted to subsequent generations
(8, 24). Mutations in the coding region of the MEN 1
gene were not detected in 5% to 10% of MEN1 pa-
tients (8, 21, 24, 25). It is possible that additional
mutations in the promoter or untranslated regions
or a large germline deletion involving theMEN1 gene
might occur. The mutations are not only diverse in
their types but scattered throughout the coding re-
gion of theMEN1 gene. Despite the identification of a
large number of mutations, no clear phenotype-genotype
correlation has yet been discerned.
LOH on 11q13 was detected in MEN1-associated
tumors of our MEN1 patients (5, 13, 16, 17, 23).
Evidence that MEN1 is a tumor suppressor gene has
been provided by the demonstration of somatic ge-
netic alterations (LOH on 11q13) in MEN1 tumors,
which would inactivate the remaining normal allele
and so unmask the inherited MEN1 mutation on the
other allele (Figure 4).
Fig. 3. Schematic representation of the mutations identified in the MEN1 gene. Exon 1, the 5’part of exon 2, and the distal part of
exon 10 (diagonally hatched box) are untranslated regions of the gene. The coding regions of the gene are denoted by a
nonhatched box. The start (ATG) and the stop (TGA) codons are indicated within exon 2 and exon 10, respectively. The locations of
the mutations are shown under the gene structure. FS, frameshift mutation ; NS, nonsense mutation ; MS, missense mutation ; IF,
in-frame deletion ; SP, splice site mutation. Underlined mutations denote somatic mutations.
Fig. 4. Inactivation of both copies of theMEN1 gene contributes to tumorigenesis in MEN1. Patients are born heterozygous for the
mutant allele of MEN1 (star). In endocrine cells, a second somatic mutation, in this example a partial deletion of chromosome 11
(striped), results in loss of the normal MEN1 allele. Sequential inactivation of both copies of the MEN1 gene leads to endocrine
tumors.
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Prolactinoma dominant of MEN1 family
Three families with the prolactinoma variant ofMEN1,
which is characterized by hyperparathyroidism (88-
100%), high penetrance of prolactinoma (37-75%),
and infrequent expression of gastrinoma (2.5-12%),
were reported (26). Of these three families, two had
different MEN1 mutations (Y312X and R460X). The
third family showed no mutations but tight linkage
of MEN1 to 11q13 (27). We reported an unusual
MEN1 family in which four of five mutation carriers
were affected and have developed prolactinoma (28).
Our cases, which were initially considered as fa-
milial prolactinomas, later were found to show unusual
features of MEN1. Parathyroid tumors are usually
the first manifestation of MEN1 (1-4). However,
prolactinomas were the first lesion diagnosed in this
family. Detection of germline mutation of 357del4
in the family prompted us to carefully examine MEN1
phenotypes. Genetic examinations are useful as di-
agnostic tools for any rare or unusual cases of MEN1.
The 357del4 were encountered frequently in many
MEN1 patients (4). Because there were no prominent
clinical features in families with the deletion, un-
known genetic factors other thanMEN1 mutation
may contribute to a prolactinoma-dominant pheno-
type.
Familial isolated hyperparathyroidism
Familial hyperparathyroidism may occur as familial
isolated hyperparathyroidism (FIHP) or as part of
an inherited syndrome, in particular MEN1, MEN2A,
and hyperparathyroidism-jaw tumor syndrome.
Families with FIHP were reported to have no MEN1
germline mutations by several groups (23, 24, 29,
30). However, some of the FIHP families had a milder
variant of MEN1, which is associated with a func-
tionally milder missense mutation (31-35).
Familial pituitary tumors
Familial pituitary tumors are defined as the oc-
currence of at least 2 cases of pituitary tumors in a
family that does not exhibit any other manifesta-
tions of MEN1 or Carney complex. Familial pitui-
tary tumors are extremely rare. Only 85 cases
occurring in 36 families have been reported in the
literature. In our review of familial pituitary tumors,
74% of cases were acromegaly or gigantism. Further-
more, 23 families showed familial GH-producing
tumors. This incidence of GH-secreting tumors in
familial pituitary tumors is much higher than the
4 -27% in MEN1 patients with pituitary tumors (1,
2, 4, Table 2). In addition, the majority of reported
cases showing acromegaly or gigantism are diag-
nosed before the age of 30 years. We reported 2
brothers with GH-secreting adenomas that exhib-
ited LOH at 11q13 (23, 38). Recently, Gadelha et
al. also demonstrated LOH at 11q13 in all GH-secreting
adenomas from 2 families with familial GH-producing
tumors (39). Therefore, familial pituitary tumors were
considered a candidate for phenotypic variants of
MEN1. However, we demonstrated no germline
MEN1 mutations in 3 families with familial pituitary
tumors (23). The result was confirmed in several
laboratories (30, 32, 36, 37). These findings suggest
the presence of another tumor suppressor gene lo-
cated at 11q13. Taken together, familial pituitary
tumors seem to be a different clinical entity from
MEN1.
MEN1 phenocopy without germline MEN1
mutation
Phenocopies have to be considered carefully in
MEN1, because of the high frequency of common
lesions such as primary hyperparathyroidism and
prolactinoma in the non-MEN1 population. We present
a patient showing primary hyperparathyroidism and
prolactinoma as an example. She did not show any
family history of endocrine tumors. No germline
mutations of theMEN1 were detected, however, two
independent somatic mutations of the MEN1 gene
(K119del and 864del8bp) were identified in the
parathyroid tumor (Figure 3). Whether both alleles
of MEN1 are inactivated by the two independent so-
matic mutations or not remains to be elucidated. Be-
cause the prolactinoma responded well to bromocriptine
therapy, surgical intervention is not necessary at
present.
Somatic MEN1 mutations in sporadic endo-
crine tumors
Previous studies on sporadic non-MEN1 endo-
crine tumors showed that LOH involving 11q13
occurs in 5% to 50% of cases, implying that somatic
mutations of the MEN1 gene contribute to the eti-
ology of these tumors (14, 15). Subsequent studies
detected somaticMEN1mutations in 13% of sporadic
parathyroid tumors, 39% of gastrinomas, 17% of
insulinomas, and 36% of bronchial carcinoid tumors
(4). However, we revealed that somatic MEN1 mu-
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tations in sporadic pituitary tumors were very in-
frequent at 3% (40). The result was confirmed in
several laboratories (41, 42). In distribution and type,
somatic mutations of the MEN1 gene were similar
to germline mutations. The observation that the
tumors having a somatic MEN1 mutation had 11q13
LOH suggested that inactivation of theMEN1 gene
contributes to tumorigenesis in a subset of sporadic
endocrine tumors.
Function of menin
Initial analysis of the predicted amino acid sequence
did not reveal homology to any other protein, sequence
motif, or signal peptide (20). Menin is primarily lo-
cated in the nucleus (43). Using a yeast 2-hybrid
screen with menin as the bait, Agarwal et al. found
that menin directly interacts with JunD, to repress
transcriptional activation mediated by JunD (44).
Several naturally occurring and clustered MEN1
missense mutations disrupted menin interaction with
JunD. It is hoped that future study of the MEN1
gene product and the biochemical pathways in which
it functions will shed light upon the reasons why
endocrine tissues are preferentially susceptible to loss
of menin function, and may also suggest new ap-
proaches to prevention or treatment of MEN1-associated
tumors.
Genetic screening in MEN1
Genetic testing for germline mutations of theMEN1
gene is a good way to clarify the diagnosis in an index
patient. Because the great diversity and widely scat-
tered locations of the MEN1 mutations and lack of
genotype-phenotype correlations make such muta-
tional screening time-consuming and expensive,
genetic testing is not widely available. However, a
DNA test that indicates an individual is not at risk
would rule out the need for further clinical investi-
gations. At present, it is suggested that mutant gene
carriers should undergo biochemical screening at
least once per annum, and also have pituitary and
abdominal imaging. Genetic testing in patients with
sporadic endocrine tumors should be performed,
1) in patients with two or more MEN1-associated
tumors, 2) in patients with multiple parathyroid tu-
mors, and 3) in patients with Zollinger-Ellison syn-
drome, 15% to 40% of whom will have coexistent
MEN1.
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